NasdaqGS:BMRNBiotechs
Is VOXZOGO’s Hypochondroplasia Data and Amicus Deal Reshaping the Investment Case for BioMarin (BMRN)?
BioMarin Pharmaceutical recently reported positive Phase 3 results for VOXZOGO in children with hypochondroplasia and advanced multiple regulatory filings and approvals, while integrating Amicus Therapeutics’ rare-disease drugs GALAFOLD and POMBILITI + OPFOLDA into its portfolio.
This combination of pipeline progress and portfolio expansion underscores how BioMarin is deepening its focus on genetically driven rare skeletal and metabolic disorders.
We’ll now examine how VOXZOGO’s progress in...